Health and Medicine
PUBLISHED
6
A drug that fights the “urge to pee” in women with overactive bladders could soon become available over the counter in the UK, after regulatory bodies are asking women and doctors to share their views on the subject. It's thought one in six women have symptoms associated with an overactive bladder in the UK and millions of women worldwide.
The rest of this article is behind a paywall. Please sign in or subscribe to access the full content.The drug, called Aquitte, is currently available for women with overactive bladder problems, but it is now being considered for reclassification to allow more access to those that need it.
The consultation will last three weeks and is made by the Medicines and Healthcare products Regulatory Agency, and you can submit any opinions you may have if you have experience with the condition here.
Symptoms of an overactive bladder involve needing to urinate over eight times a day and multiple times a night, and this often cannot be controlled by behavior or training alone.
“When it comes to sensitive issues such as bladder control, speaking to a GP may act as a barrier for some women to seek help. Reclassification of Aquiette would enable women to access vital medication without needing a prescription,” said Minister for Women’s Health Maria Caulfield in a statement.
“Making it easier for women to access healthcare is essential in supporting them to live well and reducing the gender health gap.
“I encourage any women who have experienced these symptoms to make your voices heard by responding to the call for evidence.”
If the drug is reclassified, GPs would be supplied with materials allowing them to identify those with an overactive bladder and that can be given the medicine safely.
“Living with an overactive bladder can be extremely difficult, which is why it’s so important that we hear from as many people and women’s groups as possible,” said Dr Laura Squire, Chief Healthcare Quality and Access Officer at the MHRA.
“We are thoroughly committed to improving access to medicines where it is safe to do so.”
[H/T: BBC]
